Highest-materiality recent filing
Boston Scientific enters $2B accelerated share repurchase, expects $0.02 EPS accretion in FY2026
ASR with JPMorgan for $2B; receives ~30.4M shares upfront at $52.68 (80% of repurchase price).
Boston Scientific invests $1.5B for ~34% stake in MiRus, gains option to acquire TAVR system for $3B
Paid $1.5B cash for 33.75% non-voting equity in MiRus; exclusive call option to buy TAVR business for $3.0B upon clinical/regulatory milestones.
Approved removal of supermajority voting provisions and officer exculpation under Delaware law.
Boston Scientific Q1 2026 net sales $5.20B (+11.6% reported), adj EPS $0.80 (guidance $0.78-$0.80)
GAAP EPS $0.90 vs $0.45 YoY; adjusted EPS $0.80 vs $0.75 YoY, at top of guidance.
Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results
HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).
Boston Scientific enters $11B credit facilities; $8B committed for Penumbra acquisition
$3.0B revolving credit agreement matures Feb 2031 with two one-year extension options.
Boston Scientific boosts buyback by $4B to $5B; appoints two new directors
Board approved additional $4.0B stock repurchase authorization, total available now $5.0B.
Director Yoshiaki Fujimori will not stand for re-election at Boston Scientific's 2026 annual meeting
Yoshiaki Fujimori informed Boston Scientific on Feb 2, 2026, that he will not seek re-election.
Boston Scientific reports Q4 and full year 2025 results, announces acquisitions
Q4 2025 net sales $5.286B, up 15.9% reported; GAAP EPS $0.45, adjusted EPS $0.80.
Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)
Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.
Penumbra shareholders elect cash ($374/share) or stock (3.8721 BSX shares/share); proration targets 73.26% cash, 26.74% stock.
2026 Annual Bonus Plan approved; bonus pool 0%-150% of target based on global sales, adjusted EPS, operating income, and sustainability goals.
John Sununu to not stand for re-election to Boston Scientific board at 2026 meeting
John E. Sununu will not stand for re-election at the 2026 Annual Meeting; no disagreement cited.
GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.
Boston Scientific EVP/Peripheral Interventions President Mirviss to retire in Dec 2025
Jeffrey B. Mirviss will retire as EVP and President, Peripheral Interventions effective Dec 1, 2025.
GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.
Discontinuing worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems; no longer pursuing U.S. FDA or other approvals.
All 10 director nominees elected; votes ranged from ~1.147B (Mahoney) to ~1.239B (Pegus) in favor.
Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance
GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.
Boston Scientific CFO Dan Brennan to retire; Jon Monson named successor effective June 30, 2025
Dan Brennan retires as EVP & CFO effective June 29, 2025; will remain senior advisor to October 3, 2025.
Boston Scientific subsidiary prices €1.5B senior notes to refinance 2025 maturity
AMS Europe issued €850M 3.000% notes due 2031 and €650M 3.250% notes due 2034.
Director Charles J. Dockendorff will not stand for re-election at the 2025 Annual Meeting, effective after meeting.
Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.
Boston Scientific reaches preliminary settlement of derivative lawsuits over LOTUS Edge recall
On January 8, 2025, a U.S. district court granted preliminary approval of a settlement of two shareholder derivative actions related to the LOTUS Edge recall.
Boston Scientific approves 2025 bonus plan and two performance share programs
2025 Annual Bonus Plan: target bonus pool with payout 0%-150% based on global sales, adjusted EPS, operating income and ESG goals.
Boston Scientific completes $3.7B acquisition of Axonics; enters sacral neuromodulation market
Purchase price $71/share, equity value $3.7B, enterprise value $3.3B net of cash.
Boston Scientific resumes AVANT GUARD trial in drug-naïve persistent AFib patients
AVANT GUARD trial resumed after assessment of observations and DMC input.
Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY
Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.
Boston Scientific appoints David Habiger to Board of Directors
Board expanded from 10 to 11 members; Habiger effective July 30, 2024.
Q2 net sales $4.120B, up 14.5% reported (16.1% operational, 14.7% organic); GAAP EPS $0.22, adjusted EPS $0.62 vs guidance $0.57-$0.59.
Boston Scientific appoints Dr. Cheryl Pegus to board; amends $2.75B credit facility
Dr. Cheryl Pegus elected to board as tenth director, effective May 8, 2024; will serve on compensation and risk committees.
Boston Scientific shareholders approve bylaw amendments and elect directors at annual meeting
All nine director nominees elected with votes ranging from 1.17B to 1.25B in favor.
GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.
Boston Scientific gets FTC Second Request for Axonics merger; closing expected H2 2024
FTC issued Second Request under HSR Act on April 3, 2024, extending waiting period.
Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025
On April 23, 2025, Boston Scientific Corporation (the “Company”) announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025
Charles J. Dockendorff informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders
appointed David C. Habiger, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective July 30, 2024.
appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.
Max materiality 0.95 · Median 0.72 · Most common event earnings